Taiko Pharmaceutical Co.,Ltd. (4574.T)
JPY 260.0
(-2.62%)
JPY 260.0
(-2.62%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2022 | 15.04 Billion JPY | -33.23% |
| 2021 | 22.53 Billion JPY | -29.04% |
| 2020 | 31.75 Billion JPY | 24.67% |
| 2019 | 25.47 Billion JPY | 17.93% |
| 2018 | 21.6 Billion JPY | 5.51% |
| 2017 | 20.47 Billion JPY | 8.96% |
| 2016 | 18.78 Billion JPY | 15.22% |
| 2015 | 16.3 Billion JPY | -12.32% |
| 2014 | 18.59 Billion JPY | 11.89% |
| 2013 | 16.62 Billion JPY | 27.7% |
| 2012 | 13.01 Billion JPY | 6.16% |
| 2011 | 12.26 Billion JPY | 8.96% |
| 2010 | 11.25 Billion JPY | -19.21% |
| 2009 | 13.92 Billion JPY | 21.55% |
| 2008 | 11.46 Billion JPY | 7.72% |
| 2007 | 10.63 Billion JPY | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 Q2 | 15.63 Billion JPY | 8.55% |
| 2023 Q1 | 14.4 Billion JPY | -4.27% |
| 2023 Q3 | 15.81 Billion JPY | 1.13% |
| 2022 Q1 | 19.71 Billion JPY | -12.52% |
| 2022 FY | 15.04 Billion JPY | -33.23% |
| 2022 Q4 | 15.04 Billion JPY | -8.67% |
| 2022 Q3 | 16.47 Billion JPY | -5.44% |
| 2022 Q2 | 17.42 Billion JPY | -11.63% |
| 2021 Q2 | 27.2 Billion JPY | -4.89% |
| 2021 Q4 | 22.53 Billion JPY | -21.02% |
| 2021 Q3 | 28.53 Billion JPY | 4.86% |
| 2021 FY | 22.53 Billion JPY | -29.04% |
| 2021 Q1 | 28.6 Billion JPY | 0.0% |
| 2020 Q2 | 27.2 Billion JPY | 6.8% |
| 2020 FY | 31.75 Billion JPY | 24.67% |
| 2020 Q1 | 25.47 Billion JPY | 5.66% |
| 2020 Q3 | 29.78 Billion JPY | 9.47% |
| 2019 FY | 25.47 Billion JPY | 17.93% |
| 2019 Q1 | 21.6 Billion JPY | 4.25% |
| 2019 Q2 | 20.21 Billion JPY | -6.4% |
| 2019 Q4 | 24.1 Billion JPY | 16.29% |
| 2019 Q3 | 20.73 Billion JPY | 2.54% |
| 2018 FY | 21.6 Billion JPY | 5.51% |
| 2018 Q2 | 19.18 Billion JPY | -6.29% |
| 2018 Q1 | 20.47 Billion JPY | 4.85% |
| 2018 Q3 | 19.91 Billion JPY | 3.79% |
| 2018 Q4 | 20.71 Billion JPY | 4.06% |
| 2017 Q3 | 18.32 Billion JPY | 1.35% |
| 2017 FY | 20.47 Billion JPY | 8.96% |
| 2017 Q4 | 19.52 Billion JPY | 6.56% |
| 2017 Q2 | 18.07 Billion JPY | -3.78% |
| 2017 Q1 | 18.78 Billion JPY | 1.87% |
| 2016 Q4 | 18.44 Billion JPY | 8.63% |
| 2016 Q2 | 15.45 Billion JPY | -5.2% |
| 2016 Q3 | 16.97 Billion JPY | 9.83% |
| 2016 FY | 18.78 Billion JPY | 15.22% |
| 2016 Q1 | 16.3 Billion JPY | -5.53% |
| 2015 Q1 | 18.59 Billion JPY | 9.52% |
| 2015 Q4 | 17.26 Billion JPY | 6.05% |
| 2015 FY | 16.3 Billion JPY | -12.32% |
| 2015 Q2 | 15.13 Billion JPY | -18.65% |
| 2015 Q3 | 16.27 Billion JPY | 7.57% |
| 2014 Q2 | 16.03 Billion JPY | -3.55% |
| 2014 FY | 18.59 Billion JPY | 11.89% |
| 2014 Q3 | 14.54 Billion JPY | -9.28% |
| 2014 Q1 | 16.62 Billion JPY | 5.32% |
| 2014 Q4 | 16.98 Billion JPY | 16.76% |
| 2013 Q4 | 15.78 Billion JPY | 13.92% |
| 2013 Q1 | 13.01 Billion JPY | 2.7% |
| 2013 Q2 | 13.14 Billion JPY | 0.99% |
| 2013 FY | 16.62 Billion JPY | 27.7% |
| 2013 Q3 | 13.85 Billion JPY | 5.4% |
| 2012 FY | 13.01 Billion JPY | 6.16% |
| 2012 Q4 | 12.67 Billion JPY | 9.94% |
| 2012 Q3 | 11.52 Billion JPY | -2.31% |
| 2012 Q2 | 11.8 Billion JPY | -3.75% |
| 2012 Q1 | 12.26 Billion JPY | 4.98% |
| 2011 Q3 | 11.15 Billion JPY | 1.29% |
| 2011 Q4 | 11.67 Billion JPY | 4.69% |
| 2011 FY | 12.26 Billion JPY | 8.96% |
| 2011 Q2 | 11.01 Billion JPY | -2.13% |
| 2011 Q1 | 11.25 Billion JPY | -5.82% |
| 2010 FY | 11.25 Billion JPY | -19.21% |
| 2010 Q1 | 13.92 Billion JPY | -4.06% |
| 2010 Q2 | 12.52 Billion JPY | -10.09% |
| 2010 Q4 | 11.94 Billion JPY | -1.54% |
| 2010 Q3 | 12.13 Billion JPY | -3.09% |
| 2009 Q2 | 11.64 Billion JPY | 1.6% |
| 2009 Q3 | 13.46 Billion JPY | 15.66% |
| 2009 Q4 | 14.51 Billion JPY | 7.82% |
| 2009 Q1 | 11.46 Billion JPY | 0.0% |
| 2009 FY | 13.92 Billion JPY | 21.55% |
| 2008 FY | 11.46 Billion JPY | 7.72% |
| 2007 FY | 10.63 Billion JPY | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Pharma Foods International Co., Ltd. | 36.57 Billion JPY | 58.86% |
| Takeda Pharmaceutical Company Limited | 15108.79 Billion JPY | 99.9% |
| Sumitomo Pharma Co., Ltd. | 907.5 Billion JPY | 98.342% |
| Shionogi & Co., Ltd. | 1416.91 Billion JPY | 98.938% |
| Wakamoto Pharmaceutical Co.,Ltd. | 15.42 Billion JPY | 2.432% |
| Nippon Shinyaku Co., Ltd. | 263.4 Billion JPY | 94.288% |
| Kaken Pharmaceutical Co., Ltd. | 171.62 Billion JPY | 91.233% |
| Eisai Co., Ltd. | 1393.79 Billion JPY | 98.921% |
| Morishita Jintan Co., Ltd. | 17.18 Billion JPY | 12.437% |
| Hisamitsu Pharmaceutical Co., Inc. | 328.77 Billion JPY | 95.424% |
| Mochida Pharmaceutical Co., Ltd. | 158.8 Billion JPY | 90.525% |
| Fuso Pharmaceutical Industries,Ltd. | 76.46 Billion JPY | 80.322% |
| Nippon Chemiphar Co., Ltd. | 49.54 Billion JPY | 69.633% |
| Tsumura & Co. | 428.25 Billion JPY | 96.487% |
| Kissei Pharmaceutical Co., Ltd. | 260.92 Billion JPY | 94.234% |
| Torii Pharmaceutical Co., Ltd. | 133.43 Billion JPY | 88.724% |
| Towa Pharmaceutical Co., Ltd. | 430.65 Billion JPY | 96.506% |
| Fuji Pharma Co., Ltd. | 85.33 Billion JPY | 82.368% |
| Zeria Pharmaceutical Co., Ltd. | 150.53 Billion JPY | 90.005% |
| KYORIN Holdings, Inc. | 177.67 Billion JPY | 91.532% |
| Daito Pharmaceutical Co.,Ltd. | 77.7 Billion JPY | 80.638% |
| SymBio Pharmaceuticals Limited | 15.35 Billion JPY | 1.994% |
| MedRx Co., Ltd | 2.05 Billion JPY | -633.236% |
| Mizuho Medy Co.,Ltd. | 18.94 Billion JPY | 20.595% |
| Solasia Pharma K.K. | 2.55 Billion JPY | -490.039% |
| Modalis Therapeutics Corporation | 2.02 Billion JPY | -642.673% |
| ASKA Pharmaceutical Holdings Co.,Ltd. | 93.31 Billion JPY | 83.876% |
| Sawai Group Holdings Co., Ltd. | 382.02 Billion JPY | 96.062% |
| Cyfuse Biomedical K.K. | 4.21 Billion JPY | -256.979% |
| Toho Holdings Co., Ltd. | 773.42 Billion JPY | 98.055% |
| Koa Shoji Holdings Co.,Ltd. | 32 Billion JPY | 52.987% |